Ken Griffin Regeneron Pharmaceuticals, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 83,500 shares of REGN stock, worth $77.4 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
83,500
Previous 122,900
32.06%
Holding current value
$77.4 Million
Previous $118 Million
25.81%
% of portfolio
0.02%
Previous 0.02%
Shares
27 transactions
Others Institutions Holding REGN
# of Institutions
1,482Shares Held
85.5MCall Options Held
908KPut Options Held
1.3M-
Vanguard Group Inc Valley Forge, PA8.99MShares$8.34 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$7.83 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY8.28MShares$7.68 Billion0.77% of portfolio
-
State Street Corp Boston, MA4.84MShares$4.49 Billion0.23% of portfolio
-
Capital World Investors Los Angeles, CA4.64MShares$4.3 Billion0.82% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $99.4B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...